Recruiting studies: Peptide Receptor Radionuclide Therapy

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients
Phase 2 · 1 location(s) · Tine Gregersen, MD · NCT04917484 Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for
Phase 1 · 1 location(s) · Stanford University · NCT04609592 Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors
Phase 1 · 1 location(s) · Erasmus Medical Center · NCT05870423 68Ga-DOTATATE PET/CT for the Diagnosis of Soft Tissue Sarcomas
NA · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT06500065 Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial
Phase 2/Phase 3 · 1 location(s) · The Netherlands Cancer Institute · NCT06855095 Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
Phase N/A · 2 location(s) · Methodist Health System · NCT04090034 PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours
Phase 1 · 1 location(s) · Peter MacCallum Cancer Centre, Australia · NCT05053854 Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GE
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT04086485 Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Meta
Phase 2 · 4 location(s) · University Hospital, Bordeaux · NCT04837885 Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide
Phase 1/Phase 2 · 1 location(s) · University Hospital, Basel, Switzerland · NCT04997317 Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of th
Phase 3 · 27 location(s) · Grupo Espanol de Tumores Neuroendocrinos · NCT05918302 PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)
Phase 3 · 2 location(s) · Tata Memorial Hospital · NCT07185672 Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroend
Phase 4 · 1 location(s) · Vanderbilt-Ingram Cancer Center · NCT06016855 Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell
Phase 2 · 3 location(s) · Weill Medical College of Cornell University · NCT05583708 A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
Phase 1/Phase 2 · 41 location(s) · Novartis Pharmaceuticals · NCT04939610 Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours
Phase 2 · 12 location(s) · Australasian Gastro-Intestinal Trials Group · NCT06345079

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.